Table 1 Clinical and pathologic characteristics of high-risk EC patients included in the gene-expression profiling of CTC
Feature | n (%)     | Feature | n (%)     |
|---|---|---|---|
Age (years) | Â | Â | Â |
 Mean | 69 |  |  |
FIGO Stage | Â | Lymphovascular invasion | Â |
 I | 15 (44.15) |  Positive | 6 (17.6) |
 II | 2 (5.8) |  Negative | 15 (44.1) |
 III | 11 (32.35) |  Unknown | 13 (38.2) |
 IV | 6 (17.64) | Lymph node metastasis |  |
Histology |  |  Positive | 12 (35.3) |
 Endometrioid | 19 (55.9) |  Negative | 20 (58.8) |
 Serous | 10 (29.4) |  Unknown | 2 (5.9) |
 Clear cell | 5 (14.7) | Recurrence |  |
Grade |  |  No | 18 (52.9) |
 Well differentiated (G1) | 4 (11.8) |  Yes | 15 (44.1) |
 Moderately differentiated (G2) | 6 (17.6) |  Unknown | 1 (2.9) |
 Poorly differentiated (G3) | 21 (61.8) | First treatment |  |
 Unknown | 3 (8.8) |  Radiotherapy | 4 (11.8) |
Myometrial invasion |  |  Chemotherapy | 7 (20.6) |
 <50% | 13 (38.2) |  None | 17 (50) |
 >50% | 18 (52.9) |  Unknown | 6 (17.6) |
 Unknown | 3 (8.8) |  |  |